<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264692</url>
  </required_header>
  <id_info>
    <org_study_id>AC-067A201</org_study_id>
    <nct_id>NCT01264692</nct_id>
  </id_info>
  <brief_title>Essential Hypertension</brief_title>
  <acronym>REDUCE-1</acronym>
  <official_title>A Multi-center, Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of 10 mg of ACT-280778 in Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral
      administration of ACT 280778 on DBP compared to placebo after 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean(c) trough(d) SiDBP</measure>
    <time_frame>Baseline to day 28</time_frame>
    <description>Change from baseline(b) to Day 28 (± 2 days) of Period 2 (Visit 7)in mean(c) trough(d) SiDBP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean trough SiSBP.</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Change from baseline to Day 28 (± 2 days) of Period 2 (Visit 7) in mean trough SiSBP.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-280778</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Amlodipine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-280778</intervention_name>
    <description>10 mg once daily for 28 ± 2 days</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral capsules matching ACT-280778</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>10 mg once daily for 28 ± 2 days</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18 to 75 years (inclusive) at screening.

          -  Body mass index (BMI) between 18 and 35 kg/m2 (inclusive) and body weight at least 50
             kg at screening and prior to enrollment.

          -  12-lead ECG without clinically relevant abnormalities measured at screening.

          -  Clinical chemistry, hematology, coagulation, virus serology, and urinalysis test
             results not deviating to a clinically relevant extent from the normal range at
             screening.

          -  Signed informed consent in the local language prior to any study-mandated procedure

        Exclusion Criteria:

          -  Mean SBP &gt; 180 mmHg.

          -  Severe, malignant, or secondary hypertension.

          -  Episodes of hypertensive crisis or hypertensive emergency within 6 months prior to
             enrollment.

          -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal
             reactions considered to be of clinical significance.

          -  E6 Severe coronary artery disease indicated by myocardial infarction, percutaneous
             coronary intervention, or coronary artery bypass graft within the last 12 months prior
             to enrollment.

          -  Angina pectoris within 6 months prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kasra Shakeri-Nejad, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Investigative Site 4000</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 1003</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 1008</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 1004</name>
      <address>
        <city>Givataim</city>
        <zip>53583</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 1009</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 1000</name>
      <address>
        <city>Jerusalem</city>
        <zip>91004</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 1006</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 1007</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 1005</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 1010</name>
      <address>
        <city>Tel Aviv</city>
        <zip>66872</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 1012</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 3001</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical InvestigativeSite 3003</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 4001</name>
      <address>
        <city>Belgrade</city>
        <zip>11040</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 3004</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 3002</name>
      <address>
        <city>Beograd-Zemun</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 3000</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site 4002</name>
      <address>
        <city>Pancevo</city>
        <zip>26000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2010</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

